A community-based model of rapid autopsy in end-stage cancer patients

Alsop, Kathryn; Thorne, Heather; Sandhu, Shahneen; Hamilton, Anne; Mintoff, Christopher; Christie, Elizabeth L.; Spruyt, Odette; Williams, Scott; McNally, Orla; Mileshkin, Linda; Ananda, Sumitra; Hallo, Julene; Loi, Sherene; Scott, Clare L.; Savas, Peter; Devereux, Lisa; O′Brien, Patricia J.; Gunawardena, Sameera A.; Hampson, Clare; Strachan, Kate; Jaravaza, Rufaro Diana; Francis, Victoria; Young, Gregory; Ranson, David; Samaranayake, Ravindra; Stevens, David P.; Boyle, Samantha; Fedele, Clare G.; Topp, Monique; Ho, Gwo Yaw; Teo, Zhi L.; Taylor, Renea A.; Papargiris, Melissa; Lawrence, Mitchell G.; Wang, Hong; Risbridger, Gail P.; Haynes, Nicole M.; Medon, Mikolaj; Johnstone, Ricky W.; Vidacs, Eva; Arnau, Gisela Mir; Vergara, Ismael A.; Papenfuss, Anthony T.; McArthur, Grant A.; Waring, Paul; Carvosso, Shirley; Angel, Christopher; Gyorki, David E.; Solomon, Benjamin; Mitchell, Gillian; Shanley, Sue; Francis, Prudence A.; Dawson, Sarah-Jane; Haffenden, Amy; Tidball, Erin; Volchek, Mila; Pyman, Jan; Madadin, Mohammed; Leditschke, Jodie; Cordner, Stephen; Shackleton, Mark; Bowtell, David D.L.

doi:10.1038/nbt.3674

Cited by 71 publications

(82 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Publications on posthumous tissue collection programs are increasing in popularity, [5, 6] but to our knowledge, none have discussed the donors perceptions about participating in such programs. Improved understanding of their perceptions could lead to greater gains in knowledge, increase enrollment of patients, allow more centers to create RTD programs, and potentially allow consortia of RTD centers.…”

Section: Introductionmentioning

confidence: 99%

Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program

Quinn

Pentz

Muñoz-Antonia

et al. 2018

Patient Education and Counseling

View full text Add to dashboard Cite

Objective The collection of posthumous tissue from advanced stage lung cancer patients is beneficial to medical science. Recruiting living patients to a Rapid Tissue Donation Program (RTD) poses several psychosocial challenges and little is known about perceptions of joining this type of program. This study qualitatively examined perceptions of advanced stage lung cancer patients (n=14) participating in a lung cancer RTD program, their NoK (n=11), and physicians (n=6) at the Thoracic Oncology Clinic at H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida USA. Methods Semi-structured interviews were conducted with participants and interview transcripts were analyzed using the constant comparison method. Results Majority of patients joined to give back to research, discussed participation with family members, and desired for family to receive information about the use of the tissue after their death. All participating NoK were supportive of their family member's decision. Physicians described the program as running smoothly, but provided suggestions for process improvements. Conclusion Participants joined with intention to give back to research community and families were supportive of loved one's participation in RTD. Physicians agreed with overall process. Practice implications Key factors for a successful RTD program is tailoring to institutional and individual needs.

show abstract

Section: Introductionmentioning

confidence: 99%

Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program

Quinn

Pentz

Muñoz-Antonia

et al. 2018

Patient Education and Counseling

View full text Add to dashboard Cite

show abstract

“…Two particular lines, MDA PCa 118a and MDA PCa 118b, were established as sub-cutaneous PDXs, providing a unique model of androgen-independent prostate cancer that induces a robust osteoblastic reaction in bone-like matrix and soft tissue [30]. Much more progress has been achieved through the recent utilisation of warm autopsy specimens, although the take rate from postmortem specimens is less than that of palliative metastatic lesions, such as those used by the Vessella group [22]. In Australia, an oncology collaboration established a warm autopsy programme to collect specimens from men who failed contemporary treatments.…”

mentioning

confidence: 98%

“…However, even for these samples, the take rate is still only 25-30 % [22]. The sources of tissue vary considerably with this subsequently affecting the quality of the specimens used for engraftment.…”

mentioning

confidence: 99%

“…In Australia, an oncology collaboration established a warm autopsy programme to collect specimens from men who failed contemporary treatments. Called CASCADE (Cancer tissue collection after death), this is a carefully crafted programme of autopsy of cancer patients, involving senior pathologists, palliative care, medical oncologists, familial cancer clinicians and scientists [22]. The Slow proliferative activity and lack of transplantability Select more rapidly proliferating tumours, e.g.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Patient-Derived Prostate Cancer: from Basic Science to the Clinic

Risbridger

Taylor

2016

HORM CANC

View full text Add to dashboard Cite

Systems that model cancer form the backbone of research discovery, and their accuracy and validity are a key determinant to ensure successful translation. In many tumour types, patient-derived specimens are an important model of choice for pre-clinical drug development. In this review, we consider why this has been such a challenge for prostate cancer, resulting in relatively few patient-derived xenografts (PDXs) of prostatic tumours compared to breast cancers, for example. Nevertheless, with only a few patient specimens and PDXs, we exemplify in three vignettes how important new clinical insights were obtained resulting in benefit for future men with prostate cancer.

show abstract

“…Additionally, a better understanding of the molecular function of mutant ARs is required to achieve maximal patient benefit. The field has traditionally been limited by a scarcity of CRPC models for studying AR mutant function, but new models derived from patient metastases and CTCs, such as patient-derived xenografts and organoids, are emerging (Gao et al 2014, Alsop et al 2016. As these models encompass the diversity of disease and AR alterations, they are likely to have a profound impact on our knowledge of aberrant AR signaling.…”

Section: Gata2 Oct1mentioning

confidence: 99%

Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence

Coutinho¹,

Day²,

Tilley³

et al. 2016

Endocrine-Related Cancer

150

122

View full text Add to dashboard Cite

The androgen receptor (AR) signaling axis drives all stages of prostate cancer, including the lethal, drug-resistant form of the disease termed castration-resistant prostate cancer (CRPC), which arises after failure of androgen deprivation therapy (ADT). Persistent AR activity in spite of ADT and the second-generation AR-targeting agents enzalutamide and abiraterone is achieved in many cases by direct alterations to the AR signaling axis. Herein, we provide a detailed description of how such alterations contribute to the development and progression of CRPC. Aspects of this broad and ever-evolving field specifically addressed in this review include: the etiology and significance of increased AR expression; the frequency and role of gain-of-function mutations in the AR gene; the function of constitutively active, truncated forms of the AR termed AR variants and the clinical relevance of alterations to the activity and expression of AR coregulators. Additionally, we examine the novel therapeutic strategies to inhibit these classes of therapy resistance mechanisms, with an emphasis on emerging agents that act in a manner distinct from the current ligand-centric approaches. Throughout, we discuss how the central role of AR in prostate cancer and the constant evolution of the AR signaling axis during disease progression represent archetypes of two key concepts in oncology, oncogene addiction and therapy-mediated selection pressure.

show abstract

A community-based model of rapid autopsy in end-stage cancer patients

Cited by 71 publications

References 28 publications

Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program

Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program

Patient-Derived Prostate Cancer: from Basic Science to the Clinic

Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence

Contact Info

Product

Resources

About